5′‐(<i>E</i>)‐Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA–GalNAc Conjugates
Rubina Parmar(Alnylam Pharmaceuticals (United States)), Vasant Jadhav(Alnylam Pharmaceuticals (United States)), Rachel Meyers(Alnylam Pharmaceuticals (United States)), Yi Pei(United States Military Academy), Donald J. Foster(Alnylam Pharmaceuticals (United States)), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Jennifer L. S. Willoughby(Alnylam Pharmaceuticals (United States)), Benjamin Brigham(Alnylam Pharmaceuticals (United States)), Martin A. Maier(Alnylam Pharmaceuticals (United States)), Walter Strapps, Christopher S. Theile(Alnylam Pharmaceuticals (United States)), Akin Akinc(Alnylam Pharmaceuticals (United States)), Muthiah Manoharan(Alnylam Pharmaceuticals (United States)), Kallanthottathil G. Rajeev(Alnylam Pharmaceuticals (United States)), Matthew G. Stanton(United States Military Academy), Jingxuan Liu(Alnylam Pharmaceuticals (United States)), Erin N. Guidry(Merck & Co., Inc., Rahway, NJ, USA (United States)), Klaus Charissé(Alnylam Pharmaceuticals (United States)), Mark T. Cancilla
Cited by 140
Related Papers
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
|Angewandte Chemie International Edition|2012|1.2k
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
|Molecular Therapy|2010|1.2k